Invitrogen™ CD18 (LFA-1 beta) Monoclonal Antibody (6.7), NovaFluor™ Yellow 755, eBioscience™

Description

Description: The 6.7 monoclonal antibody reacts with human and non-human primate (rhesus or cynomologus) CD18, which is also known as beta2 integrin. CD18 is expressed broadly by human lymphocytes and monocytes. Peripheral blood granulocytes also express CD18, but at lower levels. The 6.7 monoclonal antibody has been reported to induce the proliferation of resting T cells cultured with monocytes. This product contains 1 vial of NovaFluor conjugate and 1 vial of CellBlox Plus Blocking Buffer. Applications Tested: This 6.7 antibody has been pre-titrated and tested by flow cytometric analysis of normal human blood cells. This can be used at 5 μL (0.6 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test Master mixes: Master mixes of NFs should be made at 2-8 °C and may be made up to 4 hours ahead of time. We do not recommend storing master mixes containing NovaFluor conjugates overnight or longer. Whole Blood compatibility: When utilizing whole blood (as opposed to density-gradient-purified PBMC), we recommend lysing red blood cells in bulk prior to staining with NovaFluor conjugates.

CD18, also known as the integrin beta 2 subunit, is a 90-95 kDa type I transmembrane protein expressed on all leukocytes. It heterodimerizes with the alpha chains of CD11a, CD11b, CD11c, and CD11d to form various leukocyte (beta2) integrins, which are crucial for cellular adhesion and signaling. The CD18/CD11a complex, known as lymphocyte function-associated antigen-1 (LFA-1), plays a significant role in cellular adhesion and inflammatory reactions. CD18 also forms heterodimers with CD11b (Mac-1, CR3), CD11c, and CD11d, contributing to the processes of cell adhesion and cell-surface mediated signaling. These integrins are essential for proper leukocyte migration and mediating intercellular contacts. The absence of CD18 leads to leukocyte adhesion deficiency type I (LAD1), a condition characterized by impaired leukocyte migration. Severe reduction in CD18 expression can result in the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin, which can mediate leukotoxin-induced cytolysis. Defects in the CD18 gene are the cause of LAD1, and two transcript variants encoding the CD18 protein have been identified. The integrin-mediated responses are often a composite of the functions of its individual subunits, highlighting the importance of CD18 in immune function and disease.